Trial Profile
Safety and compliance of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2018
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2018 New trial record
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society